Mostrar el registro sencillo del ítem

dc.contributor.author
Bissio, E.  
dc.contributor.author
Barbás, M. G.  
dc.contributor.author
Bouzas, M. B.  
dc.contributor.author
Cudola, A.  
dc.contributor.author
Salomon, Horacio Eduardo  
dc.contributor.author
Espínola, L.  
dc.contributor.author
Fernández Giuliano, S.  
dc.contributor.author
Kademián, S.  
dc.contributor.author
Mammana, L.  
dc.contributor.author
Suarez Ornani, M. L.  
dc.contributor.author
Ravasi, G.  
dc.contributor.author
Vila, M.  
dc.contributor.author
Zapiola, I.  
dc.contributor.author
Falistocco, C.  
dc.date.available
2018-06-08T20:00:53Z  
dc.date.issued
2017-02  
dc.identifier.citation
Bissio, E.; Barbás, M. G.; Bouzas, M. B.; Cudola, A.; Salomon, Horacio Eduardo; et al.; Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014–15; Oxford University Press; Journal of Antimicrobial Chemotherapy; 72; 2; 2-2017; 504-510  
dc.identifier.issn
0305-7453  
dc.identifier.uri
http://hdl.handle.net/11336/47971  
dc.description.abstract
Background: In Argentina, current national guidelines recommend starting with NNRTI-based regimens. Recently, there have been some local reports regarding concerning levels of NNRTI-transmitted resistance, but surveillance has never been carried out at a national level. Objectives: To determine the prevalence of HIV drug resistance in people starting ART in Argentina using a WHOproposed methodology. Methods: This was a cross-sectional, nationally representative study. Twenty-five antiretroviral-dispensing sites throughout the country were randomly chosen to enrol at least 330 persons starting ART, to generate a point prevalence estimate of resistance-associated mutations (RAMs) with a 5% CI (for the total population and for those without antiretroviral exposure). All consecutive patients older than 18 years starting or restarting ART in the chosen clinics were eligible. Samples were processed with Trugene and analysed using the Stanford algorithm. Results: Between August 2014 and March 2015, we obtained 330 samples from people starting ART. The mean±SD age was 35±11 years, 63.4% were male, 16.6% had prior antiretroviral exposure and the median (IQR) CD4 count was 275 cells/mm3 (106-461). The prevalence of RAMs found was 14% (±4%) for the whole population (3% NRTI-RAMs; 11% NNRTI-RAMs and 2%PI-RAMs) and 13% (+4%) for those without prior antiretroviral exposure (3%, 10% and 2%, respectively). The most common mutation was K103N. Conclusions: This surveillance study showed concerning levels of HIV drug resistance in Argentina, especially to NNRTIs. Due to this finding, Argentina´s Ministry of Health guidelines will change, recommending performing a resistance test for everyone before starting ART. If this is taken up properly, it also might function as a continuing surveillance tool.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Oxford University Press  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
Hiv  
dc.subject
Aids  
dc.subject
Treatment  
dc.subject
Argentina  
dc.subject.classification
Otras Ciencias Biológicas  
dc.subject.classification
Ciencias Biológicas  
dc.subject.classification
CIENCIAS NATURALES Y EXACTAS  
dc.title
Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014–15  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2018-06-06T13:38:16Z  
dc.journal.volume
72  
dc.journal.number
2  
dc.journal.pagination
504-510  
dc.journal.pais
Reino Unido  
dc.journal.ciudad
Oxford  
dc.description.fil
Fil: Bissio, E.. Fundación Centro de Estudios Infectológicos; Argentina  
dc.description.fil
Fil: Barbás, M. G.. Laboratorio Central de Córdoba; Argentina  
dc.description.fil
Fil: Bouzas, M. B.. Hospital Muñiz; Argentina  
dc.description.fil
Fil: Cudola, A.. Laboratorio Central de Córdoba; Argentina  
dc.description.fil
Fil: Salomon, Horacio Eduardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina  
dc.description.fil
Fil: Espínola, L.. Provincia de Buenos Aires. Ministerio de Salud; Argentina  
dc.description.fil
Fil: Fernández Giuliano, S.. Hospital Muñiz; Argentina  
dc.description.fil
Fil: Kademián, S.. Laboratorio Central de Córdoba; Argentina  
dc.description.fil
Fil: Mammana, L.. Hospital Muñiz; Argentina  
dc.description.fil
Fil: Suarez Ornani, M. L.. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina  
dc.description.fil
Fil: Ravasi, G.. Organización Panamericana de la Salud; Estados Unidos  
dc.description.fil
Fil: Vila, M.. Organización Panamericana de la Salud; Argentina  
dc.description.fil
Fil: Zapiola, I.. Hospital Muñiz; Argentina  
dc.description.fil
Fil: Falistocco, C.. Provincia de Buenos Aires. Ministerio de Salud; Argentina  
dc.journal.title
Journal of Antimicrobial Chemotherapy  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/https://dx.doi.org/10.1093/jac/dkw445  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://academic.oup.com/jac/article/72/2/504/2374139